Drug Profile
NLA 104
Alternative Names: Monocytes/Macrophages cell therapy - Nohla TherapeuticsLatest Information Update: 28 Nov 2021
Price :
$50
*
At a glance
- Originator Nohla Therapeutics
- Class Anti-inflammatories; Cell therapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for preclinical development in Inflammation in USA (Parenteral)
- 24 Oct 2017 Preclinical trials in Inflammation in USA (Parenteral) before October 2017 (Nohla Therapeutics pipeline, October 2017)